GlobeNewswire: Tarix Pharmaceuticals Contains the last 10 of 1 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T11:14:56ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2011/09/27/457182/233330/en/Tarix-Pharmaceuticals-TXA127-Granted-Orphan-Drug-Status-for-Treatment-of-Pulmonary-Arterial-Hypertension.html?f=22&fvtc=4&fvtv=13494Tarix Pharmaceuticals' TXA127 Granted Orphan Drug Status for Treatment of Pulmonary Arterial Hypertension2011-09-27T12:30:00Z<![CDATA[CAMBRIDGE, Mass., Sept. 27, 2011 (GLOBE NEWSWIRE) -- Tarix Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has granted TXA127, the Company's lead peptide drug candidate, orphan drug status for the treatment of pulmonary arterial hypertension (PAH). Emerging science has demonstrated that the naturally occurring peptide angiotensin (1-7), the pharmaceutical ingredient in TXA127, exhibits a protective effect in animal models of PAH, suggesting a potentially beneficial role for TXA127 against this disease.]]>